Partum has developed several transfecting agent candidates that offer the potential for reduced toxicity, improved serum stability, and enhanced cellular uptake. We believe that our novel approach will improve the performance of new siRNA therapeutics and lead to fundamental breakthroughs in siRNA delivery research.

​

PAB-001 and PAB-005 are being investigated in the preclinical animal studies to determine their efficacy in siRNA delivery.